ACAT1 and Alzheimer disease: We speculate that blocking ACAT1 may increase the cholesterol content at the lipid raft domain in various membrane organelles, and it maybe through the cholesterol rich lipid raft domain that F12511 and nanoparticles alone act synergistically to benefit AD and other neurodegenerative diseases.